The ATP-gated P2X1 ion channel acts as a positive regulator of platelet responses to collagen

Thrombosis and Haemostasis

Volumn 86, Issue 5, 2001, Pages 1264-1271

  Oury, C ^a   Toth Zsamboki, E ^a   Thys, C ^a   Tytgat, J ^a   Vermylen, J ^a   Hoylaerts, M F ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Aggregation; ATP; Collagen; Platelet receptor; Shape change

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ALPHA,BETA METHYLENEADENOSINE TRIPHOSPHATE; APYRASE; BETA,GAMMA METHYLENEADENOSINE TRIPHOSPHATE; COLLAGEN; ION CHANNEL; PURINE P2X RECEPTOR; PURINE P2X1 RECEPTOR; PURINE P2X1 RECEPTOR AGONIST; PURINE P2Y RECEPTOR; PURINE P2Y1 RECEPTOR; PURINERGIC RECEPTOR STIMULATING AGENT; UNCLASSIFIED DRUG; VOLTAGE GATED CHANNEL FORMING PROTEIN; 5' ADENYLYL (BETA,GAMMA METHYLENE)DIPHOSPHONATE; 5'-ADENYLYL (BETA,GAMMA-METHYLENE)DIPHOSPHONATE; ALPHA,BETA-METHYLENEADENOSINE 5'-TRIPHOSPHATE; CALCIUM; DRUG DERIVATIVE; PURINE P2 RECEPTOR;

ARTICLE; CALCIUM TRANSPORT; CELL SHAPE; CHANNEL GATING; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DESENSITIZATION; DRUG INHIBITION; EXTRACELLULAR CALCIUM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; ION CURRENT; NONHUMAN; OOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; XENOPUS; ANIMAL; DRUG EFFECT; DRUG INTERACTION; DRUG POTENTIATION; ION CHANNEL; KINETICS; METABOLISM; PATCH CLAMP; PHYSIOLOGY;

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ANIMAL; CALCIUM; COLLAGEN; DRUG INTERACTIONS; HUMAN; ION CHANNEL GATING; ION CHANNELS; KINETICS; OOCYTES; PATCH-CLAMP TECHNIQUES; PLATELET ACTIVATION; RECEPTORS, PURINERGIC P2; SUPPORT, NON-U.S. GOV'T; XENOPUS;

EID: 0035164358     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1616060     Document Type: Article

References (38)

1. Adenine nucleotides in blood platelets
2. ADP receptors on platelets
3. Activation of ADP receptors and platelet function
4. 2 production
5. Released adenosine diphosphate stabilizes thrombin-induced human platelet aggregates
6. A key role of adenosine diphosphate in the irreversible platelet aggregation induced by the PAR1-activating peptide through the late activation of phosphoinositide 3-kinase
7. Ticlopidine selectively inhibits human platelet responses to adenosine diphosphate
8. ADP receptors and clinical bleeding disorders
9. Identification of the platelet ADP receptor targeted by antithrombotic drugs
10. Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice
11. 1-deficient mice
12. Activation of receptor-operated cation channels via P2X1 not P2T purinoceptors in human platelets
13. Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation
14. Molecular basis for ADP-induced platelet activation. II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets
15. 1 purinoceptors for platelet aggregation
16. 1 purinoceptors on rat platelets: Effect of clopidogrel
17. 1 receptors: Evidence for separate receptors stimulated by ATP and ADP on human platelets
18. 1 receptor is an ADP receptor antagonized by ATP and expressed in platelets and megakaryoblastic cells
19. ADP-receptors
20. 1 purinoceptors with α,β-methylene ATP
21. Collagen receptor signaling in platelets and megakaryocytes
22. An echistatin-like Arg-Gly-Asp (RGD)-containing sequence in the heavy chain CDR3 of a murine monoclonal antibody that inhibits human platelet glycoprotein IIb/IIIa function
23. A natural dominant negative P2X1 receptor due to deletion of a single amino acid residue
24. Pharmacological characterization of heterologously expressed ATP-gated cation channels (P2X purinoceptors)
25. Domains of P2X receptors involved in desensitization
26. 2T receptor in amplification of human platelet activation, aggregation, secretion, and procoagulant activity
27. ADP induces partial platelet aggregation without shape change and potentiates collagen-induced aggregation in the absence of Gαq
28. Antagonists of the platelet P2T receptor: A novel approach to antithrombotic therapy
29. ATP secretion occurs as an initial response in collagen-induced platelet activation
30. Dichotomous regulation of myosin phosphorylation and shape change by Rho-kinase and calcium in intact human platelets
31. Adenosine 5′-diphosphate antagonists and human platelets: No evidence that aggregation and inhibition of stimulated adenylate cyclase are mediated by different receptors
32. 2T-purinoceptors on human blood platelets
33. 1 and P2cyc receptors
34. ADP receptor antagonists and converting enzyme systems reduce platelet deposition onto collagen
35. Heterogeneity in storage pool deficiency: Studies on granule-bound substances in 18 patients including variants deficient in α-granules, platelet factor 4, β-thromboglobulin, and platelet-derived growth factor
36. Detection of local ATP release from activated platelets using cell surface-attached firely luciferase
37. AC receptors in ADP-evoked calcium signaling in human platelets
38. FcγRIIA requires a Gi-dependent pathway for an efficient stimulation of phosphoinositide 3-kinase, calcium mobilization, and platelet aggregation